Table 4.

Standardized co-efficient of baseline (t1) predictors of disease-specific QOL at six months (t2)

Baseline (t1) predictors of Disease specific QOL at 6 Months (t2)	Disease specific QOL at 6 Months (t2)
	Model 1:Predicting sexual dysfunction at 6- month (t2)	Model 2: Predicting sexual bother at 6- month (t2)	Model 3:Predicting urinary dysfunction at 6-month (t2)	Model 4:Predicting urinary bother at 6- month (t2)	Model5:Predicting urinary limitation at 6-month (t2)
Age	.10^***	−.02	.02	.01	.06
Marital status	−.05	−.03	−.06^†	.01	.01
Education level	.03	−.01	−.02	−.04	−.01
Employment	.08^*	.02	.01	.01	.02
PSA Level	.07^†	−.04	.05	.03	.01
Gleason Score	.05	.05	.01	.03	.00
Surgery (dummy coded)	−.31^***	−.37^***	.01	.09^*	−.03
Brachytherapy (dummy coded)	−.19^***	−.28^***	.29^***	.25^***	.19^***
Neoadjuvant or adjuvant	.11^**	.10^**	.05^†	.06^†	.02
Depressive symptoms at baseline (t1)	.07^*	.13^**	.14^***	.15^*	.18^***
Sexual Dysfunction at baseline (t1)	.49****
Sexual Bother at baseline (t1)		30^***
Urinary Dysfunction at baseline (t1)			47^***
Urinary Bother at baseline (t1)				.34^***
Urinary Limitation at baseline (t1)					27^***
R²_total	.36	.20	.34	.21	.15

Note. Marital Status (married = 1, not married = 0), employment status (employed= 1, not employed = 0), educational level (≤High School = 0, ≥College = 1), neoadjuvant or adjuvant treatment (neoadjuvant or adjuvant =1, no neoadjuvant or adjuvant = 0), treatment modality (surgery = 1 versus EBRT = 0; brachytherapy = 1 versus EBRT = 0).

^†

p < .10,

p < .05,

^**

p < .01,

^***

p < .001.